Cyclooxygenase-2 inhibition reduces stress-induced affective pathology

eLife

Volumn 5, Issue MAY2016, 2016, Pages

  Gamble George, Joyonna Carrie ^a,b   Baldi, Rita ^a   Halladay, Lindsay ^c   Kocharian, Adrina ^c   Hartley, Nolan ^a,b   Silva, Carolyngrace ^a   Roberts, Holly ^a   Haymer, Andre ^a   Marnett, Lawrence J ^d   Holmes, Andrew ^c   Patel, Sachin ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Section on Brain Electrophysiology and Imaging   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; APAMIN; CANNABINOID RECEPTOR; CELECOXIB; CYCLOOXYGENASE 2; LUMIRACOXIB; POTASSIUM; RIMONABANT; CYCLOOXYGENASE 2 INHIBITOR; PTGS2 PROTEIN, MOUSE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANXIETY DISORDER; ARTICLE; BASOLATERAL AMYGDALA; ELEVATED PLUS MAZE TEST; EX VIVO STUDY; FEAR; FEMALE; HYPOPHAGIA; MAJOR DEPRESSION; MALE; MOOD DISORDER; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; OPEN FIELD TEST; STRESS; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; ANIMAL; DRUG EFFECTS; METABOLISM; PHYSIOLOGICAL STRESS;

ANIMALS; BASOLATERAL NUCLEAR COMPLEX; BEHAVIOR, ANIMAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; MICE; STRESS, PHYSIOLOGICAL;

EID: 84971607320     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.14137     Document Type: Article

References (63)

1. Abdallah CG, Sanacora G, Duman RS, Krystal JH. 2015. Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annual Review of Medicine 66:509-523. doi: 10.1146/annurev-med-053013-062946
2. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. 2009. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depression and Anxiety 26:607-611. doi: 10.1002/da.20589
3. Akhondzadeh S, Jafari S. 2010. A double-blind, placebo-controlled trial of celecoxib adjunctive treatment to fluoxetine in major depression. British Journal of Clinical Pharmacology 70:291-292.
4. Atchley D, Hankosky ER, Gasparotto K, Rosenkranz JA. 2012. Pharmacological enhancement of calcium-activated potassium channel function reduces the effects of repeated stress on fear memory. Behavioural Brain Research 232:37-43. doi: 10.1016/j.bbr.2012.03.037
5. Bahi A, Al Mansouri S, Al Memari E, Al Ameri M, Nurulain SM, Ojha, S. 2014. b-caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiology & Behavior 135:119-124. doi: 10.1016/j.physbeh.2014.06.003
6. Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S. 2014. Central anandamide deficiency predicts stress-induced anxiety: Behavioral reversal through endocannabinoid augmentation. Translational Psychiatry 4:e408. doi: 10.1038/tp.2014.53
7. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington, H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. 2003. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301:386-389. doi: 10.1126/science.1083968
8. Cryan JF, Holmes, A. 2005. The ascent of mouse: Advances in modelling human depression and anxiety. Nature Reviews. Drug Discovery 4:775-790. doi: 10.1038/nrd1825
9. Dhir A, Padi SS, Naidu PS, Kulkarni SK. 2006. Protective effect of naproxen (non-selective cox-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice. European Journal of Pharmacology 535:192-198. doi: 10.1016/j.ejphar.2006.01.064
10. Di Marzo V, De Petrocellis L. 2012. Why do cannabinoid receptors have more than one endogenous ligand? Philosophical Transactions of the Royal Society B: Biological Sciences 367:3216-3228. doi: 10.1098/rstb.2011.0382
11. Duggan KC, Hermanson DJ, Musee J, Prusakiewicz JJ, Scheib JL, Carter BD, Banerjee S, Oates JA, Marnett LJ. 2011. (R)-profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nature Chemical Biology 7:803-809. doi: 10.1038/nchembio.663
12. Dulawa SC, Hen R. 2005. Recent advances in animal models of chronic antidepressant effects: The novelty-induced hypophagia test. Neuroscience and Biobehavioral Reviews 29:771-783. doi: 10.1016/j.neubiorev.2005.03.017
13. Dutta A, McKie S, Deakin JF. 2015. Ketamine and other potential glutamate antidepressants. Psychiatry Research 225:1-13. doi: 10.1016/j.psychres.2014.10.028
14. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. 2014. Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Human Psychopharmacology 29:216-223. doi: 10.1002/hup.2401
15. Fava M, Rush AJ, Alpert JE, Carmin CN, Balasubramani GK, Wisniewski SR, Trivedi MH, Biggs MM, Shores-Wilson, K. 2006. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: A replication and extension. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 51:823-835.
16. Felger JC, Miller AH. 2014. Neurotherapeutic implications of brain-immune interactions. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 39: 242-243. doi: 10.1038/npp.2013.213
17. Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le Guen E, Marlinge E, Tamouza R, Leboyer M. 2014. Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: A systematic qualitative review. Acta Psychiatrica Scandinavica 129:163-179. doi: 10.1111/acps.12211
18. Fried EI, Epskamp S, Nesse RM, Tuerlinckx F, Borsboom D. 2016. What are ’good’ depression symptoms? Comparing the centrality of DSM and non-dsm symptoms of depression in a network analysis. Journal of Affective Disorders 189:314-320. doi: 10.1016/j.jad.2015.09.005
19. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. 2003. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor ppar-alpha. Nature 425:90-93. doi: 10.1038/nature01921
20. Gaetani S, Cuomo V, Piomelli D. 2003. Anandamide hydrolysis: A new target for anti-anxiety drugs? Trends in Molecular Medicine 9:474-478. doi: 10.1016/j.molmed.2003.09.005
21. Gałecki P, Gałecka E, Maes, M, Chamielec M, Orzechowska A, Bobińska K, Lewiński A, Szemraj, J. 2012. The expression of genes encoding for COX-2, MPO, inos, and spla2-iia in patients with recurrent depressive disorder. Journal of Affective Disorders 138:360-366. doi: 10.1016/j.jad.2012.01.016
22. Gamble-George JC, Conger JR, Hartley ND, Gupta, P, Sumislawski JJ, Patel S. 2013. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology 228:401-409. doi: 10.1007/s00213-013-3042-8
23. García-Gutiérrez MS, Manzanares, J. 2011. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. Journal of Psychopharmacology 25:111-120. doi: 10.1177/0269881110379507
24. Griebel G, Holmes A. 2013. 50 years of hurdles and hope in anxiolytic drug discovery. Nature Reviews. Drug Discovery 12:667-687. doi: 10.1038/nrd4075
25. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes, A. 2013. Amygdala FAAH and anandamide: Mediating protection and recovery from stress. Trends in Pharmacological Sciences 34:637-644. doi: 10.1016/j.tips.2013.08.008
26. Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F. 2009. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. European Journal of Pharmacology 612:54-60. doi: 10.1016/j.ejphar.2009.03.076
27. Haroon E, Raison CL, Miller AH. 2012. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37:137-162. doi: 10.1038/npp.2011.205
28. Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ, Colbran RJ, Reese J, Marnett LJ, Patel S. 2013. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nature Neuroscience 16:1291-1298. doi: 10.1038/nn.3480
29. Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S. 2014. Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends in Pharmacological Sciences 35:358-367. doi: 10.1016/j.tips.2014.04.006
30. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G. 2009. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends in Pharmacological Sciences 30:484-493. doi: 10.1016/j.tips.2009.06.006
31. Hill MN, Patel S. 2013. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biology of Mood & Anxiety Disorders 3. doi: 10.1186/2045-5380-3-19
32. Janak PH, Tye KM. 2015. From circuits to behaviour in the amygdala. Nature 517:284-292. doi: 10.1038/nature14188
33. Jenniches I, Ternes S, Albayram O, Otte DM, Bach K, Bindila L, Michel K, Lutz B, Bilkei-Gorzo A, Zimmer A. 2015. Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biological Psychiatry. doi: 10.1016/j.biopsych.2015.03.033
34. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. 1996. Cox-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proceedings of the National Academy of Sciences of the United States of America 93:2317-2321 doi: 10.1073/pnas.93.6.2317. doi: 10.1073/pnas.93.6.2317
35. Kessler RC. 1997. The effects of stressful life events on depression. Annual Review of Psychology 48:191-214. doi: 10.1146/annurev.psych.48.1.191
36. Kessler RC, Chiu WT, Demler, O, Merikangas KR, Walters EE. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry 62:617-627. doi: 10.1001/archpsyc.62.6.617
37. Kessler RC, Petukhova, M, Sampson NA, Zaslavsky AM, Wittchen H-U. 2012. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the united states. International Journal of Methods in Psychiatric Research 21:169-184. doi: 10.1002/mpr.1359
38. Kozak KR, Rowlinson SW, Marnett LJ. 2000. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. The Journal of Biological Chemistry 275:33744-33749. doi: 10.1074/jbc.M007088200
39. Kozak KR, Prusakiewicz JJ, Rowlinson SW, Schneider, C, Marnett LJ. 2001. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. The Journal of Biological Chemistry 276:30072-30077. doi: 10.1074/jbc.M104467200
40. Kulmacz RJ, Lands WE. 1984. Prostaglandin H synthase. stoichiometry of heme cofactor. The Journal of Biological Chemistry 259:6358-6363.
41. Kumari B, Kumar A, Dhir A. 2007. Protective effect of non-selective and selective cox-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations. Pharmacological Reports 59:699-707.
42. Lee SH, Ledri M, Tóth B, Marchionni I, Henstridge CM, Dudok B, Kenesei K, Barna L, Szabó SI, Renkecz T, Oberoi M, Watanabe M, Limoli CL, Horvai G, Soltesz I, Katona I, Tóth B, Szabó SI. 2015. Multiple forms of endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release. Journal of Neuroscience 35:10039-10057. doi: 10.1523/JNEUROSCI.4112-14.2015
43. Ligresti A, Martos J, Wang J, Guida F, Allarà M, Palmieri V, Luongo L, Woodward D, Di Marzo V. 2014. Prostamide F(2) a receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition. British Journal of Pharmacology 171:1408-1419. doi: 10.1111/bph.12410
44. Likhtik E, Pelletier JG, Popescu AT, Paré D. 2006. Identification of basolateral amygdala projection cells and interneurons using extracellular recordings. Journal of Neurophysiology 96:3257-3265. doi: 10.1152/jn.00577.2006
45. Mangold JB, Gu H, Rodriguez LC, Bonner, J, Dickson J, Rordorf C. 2004. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism and Disposition: The Biological Fate of Chemicals 32: 566-571. doi: 10.1124/dmd.32.5.566
46. McEwen BS. 2003. Mood disorders and allostatic load. Biological Psychiatry 54:200-207. doi: 10.1016/s0006-3223(03)00177-x
47. Merali Z, Levac C, Anisman H. 2003. Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice. Biological Psychiatry 54:552-565. doi: 10.1016/s0006-3223(02)01827-9
48. Miller AH, Maletic, V, Raison CL. 2009. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65:732-741. doi: 10.1016/j.biopsych.2008.11.029
49. Müller N, Schwarz MJ, Dehning, S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller H-J, Arolt V, Riedel M. 2006. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 11:680-684. doi: 10.1038/sj.mp.4001805
50. Müller N. 2010. Cox-2 inhibitors as antidepressants and antipsychotics: Clinical evidence. Current Opinion in Investigational Drugs 11:31-42.
51. Munhoz CD, García-Bueno B, Madrigal JL, Lepsch LB, Scavone, C, Leza JC. 2008. Stress-induced neuroinflammation: Mechanisms and new pharmacological targets. Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas MéDicas E Bioló Gicas /Sociedade Brasileira De BiofííSica… [Et Al.] 41:1037-1046. doi: 10.1590/s0100-879x2008001200001
52. Papakostas GI, Ionescu DF. 2015. Towards new mechanisms: An update on therapeutics for treatment-resistant major depressive disorder. Molecular Psychiatry 20:1142-1150. doi: 10.1038/mp.2015.92
53. Pape HC, Pare, D. 2010. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiological Reviews 90:419-463. doi: 10.1152/physrev.00037.2009
54. Raison CL, Miller AH. 2013. Role of inflammation in depression: Implications for phenomenology, pathophysiology and treatment. Modern Trends in Pharmacopsychiatry 28:33-48. doi: 10.1159/000343966
55. Ramikie TS, Nyilas R, Bluett RJ, Gamble-George JC, Hartley ND, Mackie K, Watanabe M, Katona I, Patel S. 2014. Multiple mechanistically distinct modes of endocannabinoid mobilization at central amygdala glutamatergic synapses. Neuron 81:1111-1125. doi: 10.1016/j.neuron.2014.01.012
56. Rau AR, Chappell AM, Butler TR, Ariwodola OJ, Weiner JL. 2015. Increased basolateral amygdala pyramidal cell excitability may contribute to the anxiogenic phenotype induced by chronic early-life stress. Journal of Neuroscience 35:9730-9740. doi: 10.1523/JNEUROSCI.0384-15.2015
57. Ross RA. 2003. Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology 140:790-801. doi: 10.1038/sj.bjp.0705467
58. Ruehle S, Rey AA, Remmers, F, Lutz B. 2012. The endocannabinoid system in anxiety, fear memory and habituation. Journal of Psychopharmacology 26:23-39. doi: 10.1177/0269881111408958
59. Sang N, Zhang J, Chen C. 2006. Pge2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. The Journal of Physiology 572:735-745. doi: 10.1113/jphysiol.2006.105569
60. Shonesy BC, Bluett RJ, Ramikie TS, Báldi R, Hermanson DJ, Kingsley PJ, Marnett LJ, Winder DG, Colbran RJ, Patel, S. 2014. Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. Cell Reports 9:1644-1653. doi: 10.1016/j.celrep.2014.11.001
61. Sumislawski JJ, Ramikie TS, Patel, S. 2011. Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: A potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 36:2750-2761. doi: 10.1038/npp.2011.166
62. Wang W, Zhang K, Yan S, Li A, Hu X, Zhang, L, Liu C. 2011. Enhancement of apamin-sensitive medium afterhyperpolarization current by anandamide and its role in excitability control in cultured hippocampal neurons. Neuropharmacology 60:901-909. doi: 10.1016/j.neuropharm.2011.01.027
63. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. 1993. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 11:371-386. doi: 10.1016/0896-6273(93)90192-t